mRNA药物的结构和临床应用

doi:10.19586/j.2095-2341.2023.0139

生物技术进展 ›› 2024, Vol. 14 ›› Issue (1): 1-16.DOI: 10.19586/j.2095-2341.2023.0139

• 生物制品研发与技术专题 •

mRNA药物的结构和临床应用

常东峰(), 孙召朋()

石药集团巨石生物有限责任公司，石家庄 050015

收稿日期:2023-10-26 接受日期:2023-11-28 出版日期:2024-01-25 发布日期:2024-02-05
通讯作者: 孙召朋
作者简介:常东峰 E-mail: changdongfeng@cspc.cn；
基金资助:
河北省生物医药创新专项(22372405D)

Structure and Clinical Application of mRNA Drugs

Dongfeng CHANG(), Zhaopeng SUN()

CSPC Megalith Biopharmaceutical Co. ，Ltd. ，Shijiazhuang 050015，China

Received:2023-10-26 Accepted:2023-11-28 Online:2024-01-25 Published:2024-02-05
Contact: Zhaopeng SUN

摘要/Abstract

摘要：

mRNA凭借其有效性、安全性和易大规模生产等特点，在预防急性传染病方面显示出巨大的潜力。mRNA代表了一个新兴的精准医学领域，几种针对传染病和癌症等疗法的mRNA在体内和体外都显示出良好效果。mRNA稳定性好、免疫原性高、不受受体主要组织相容性复合体（major histocompatibility complex, MHC）型别的限制，且mRNA理论上可实现不同目的蛋白的体内表达，这使得开发mRNA药物更具灵活性，可用于预防和治疗多种难治性或遗传性疾病。介绍了mRNA的一级结构和高级结构，综述了mRNA药物的临床应用进展，以期帮助理解mRNA的药物功能和临床应用，为mRNA药物的发展提供方向。

关键词: mRNA结构, mRNA药物, 临床应用

Abstract:

Because of the characters of effective， safe and easy to be produced on a large scale， mRNA drugs have showed great potential on preventing viral infections. mRNA represents an emerging field of precision medicine， several mRNA drugs targeted therapies for infectious diseases and cancer have shown beneficial results both in vivo and in vitro. mRNA is stable， immunogenic， and not limited by the receptor's major histocompatibility complex （MHC） type. In theory， mRNA can achieve in vivo expression of different target proteins， which makes the development of mRNA drugs more flexible and can be used to prevent and treat many refractory or hereditary diseases. This paper introduced the primary structure and higher structure of mRNA， and summarized the progress of mRNA drugs in clinical application， which was expected to help understand the drug function of mRNA， and the clinical application， and provide the direction for the development of mRNA drugs.

Key words: mRNA structure, mRNA drugs, clinical application

中图分类号:

Q522+.2

常东峰, 孙召朋. mRNA药物的结构和临床应用[J]. 生物技术进展, 2024, 14(1): 1-16.

Dongfeng CHANG, Zhaopeng SUN. Structure and Clinical Application of mRNA Drugs[J]. Current Biotechnology, 2024, 14(1): 1-16.

图/表 1

参考文献 99

1	SAHIN U, KARIKÓ K, TÜRECI Ö. mRNA-based therapeutics-developing a new class of drugs[J]. Nat. Rev. Drug Discov., 2014, 13: 759-780.
2	PARDI N, HOGAN M J, PORTER F W, et al.. mRNA vaccines-a new era in vaccinology[J]. Nat. Rev. Drug Discov., 2018, 17: 261-279.
3	VAN LINT S, RENMANS D, BROOS K, et al.. The ReNAissanCe of mRNA-based cancer therapy[J]. Expert Rev. Vaccines, 2015, 14(2): 235-251.
4	PARDI N, MURAMATSU H, WEISSMAN D, et al.. In vitro transcription of long RNA containing modified nucleosides[J]. Meth. Mol. Biol., 2013, 969: 29-42.
5	VOGEL A B, KANEVSKY I, CHE Y E, et al.. A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates[J/OL]. BioRxiv. Preprint Server., 2020: 280818v1[2023-10-20]. .
6	JACKSON N A C, KESTER K E, CASIMIRO D, et al.. The promise of mRNA vaccines: a biotech and industrial perspective[J/OL]. NPJ Vaccines, 2020, 5: 11[2023-10-20]. .
7	WOLFF J A, MALONE R W, WILLIAMS P, et al.. Direct gene transfer into mouse muscle in vivo [J]. Science, 1990, 247(1): 1465-1468.
8	DEAL C E, CARFI A, PLANTE O J. Advancements in mRNA encoded antibodies for passive immunotherapy[J/OL]. Vaccines Basel, 2021, 9(2): 108[2023-10-20]. .
9	SHYH P T. Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273[J]. J. Pharm. Pract., 2022, 35(6): 947-951.
10	KIM S C, SEKHON S S, SHIN W R, et al.. Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency[J]. Mol. Cell. Toxicol., 2022, 18(1): 1-8.
11	CONRY R M, LOBUGLIO A F, WRIGHT M, et al.. Characterization of a messenger RNA polynucleotide vaccine vector[J]. Cancer Res., 1995, 55(7): 1397-1400.
12	WHITELAW E, COATES A, PROUDFOOT N J. Globin gene transcripts can utilize histone gene 3' end processing signals[J]. Nucleic Acids Res., 1986, 14(17): 7059-7070.
13	ZHONG C, WEI P, ZHANG Y P. Enhancing functional expression of codon-optimized heterologous enzymes in Escherichia coli BL21(DE3) by selective introduction of synonymous rare codons[J]. Biotechnol. Bioeng., 2017, 114(5): 1054-1064.
14	WANG Y, ZHANG Z, LUO J, et al.. mRNA vaccine: a potential therapeutic strategy[J/OL]. Mol. Cancer, 2021, 20(1): 33[2023-10-20]. .
15	RAMANATHAN A, ROBB G B, CHAN S H. mRNA capping: biological functions and applications[J]. Nucleic Acids Res., 2016, 44(16): 7511-7526.
16	VAN DIJK E, COUGOT N, MEYER S, et al.. Human Dcp2: a catalytically active mRNA decapping enzyme located in specific cytoplasmic structures[J]. EMBO J., 2002, 21(24): 6915-6924.
17	BRENGUES M, TEIXEIRA D, PARKER R. Movement of eukaryotic mRNAs between polysomes and cytoplasmic processing bodies[J]. Science, 2005, 310(5747): 486-489.
18	LEPPEK K, DAS R, BARNA M. Functional 5' UTR mRNA structures in eukaryotic translation regulation and how to find them[J]. Nat. Rev. Mol. Cell Biol., 2018, 19: 158-174.
19	WADHWA A, ALJABBARI A, LOKRAS A, et al.. Opportunities and challenges in the delivery of mRNA-based vaccines[J/OL]. Pharmaceutics, 2020, 12(2): E102[2023-10-20]. .
20	TREPOTEC Z, ANEJA M K, GEIGER J, et al.. Maximizing the translational yield of mRNA therapeutics by minimizing 5'-UTRs[J]. Tissue Eng. Part A, 2019, 25(1-2): 69-79.
21	ZARGHAMPOOR F, AZARPIRA N, KHATAMI S R, et al.. Improved translation efficiency of therapeutic mRNA[J]. Gene, 2019, 707: 231-238.
22	CHAUDHARY N, WEISSMAN D, WHITEHEAD K A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation[J]. Nat. Rev. Drug Discov., 2021, 20: 817-838.
23	KUDLA G, LIPINSKI L, CAFFIN F, et al.. High guanine and cytosine content increases mRNA levels in mammalian cells[J/OL].PLoS Biol., 4(6): e180[2023-10-20]. .
24	HANSON G, COLLER J. Codon optimality, bias and usage in translation and mRNA decay[J]. Nat. Rev. Mol. Cell Biol., 2018, 19: 20-30.
25	PRESNYAK V, ALHUSAINI N, CHEN Y H, et al.. Codon optimality is a major determinant of mRNA stability[J]. Cell, 2015, 160(6): 1111-1124.
26	CANNAROZZI G, SCHRAUDOLPH N N, FATY M, et al.. A role for codon order in translation dynamics[J]. Cell, 2010, 141(2): 355-367.
27	BOSSI L, ROTH J R. The influence of codon context on genetic code translation[J]. Nature, 1980, 286: 123-127.
28	KOZAK M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes[J]. Cell, 1986, 44(2): 283-292.
29	LIU Q. Comparative analysis of base biases around the stop codons in six eukaryotes[J]. Biosystems, 2005, 81(3): 281-289.
30	KARIKÓ K, MURAMATSU H, KELLER J M, et al.. Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin[J]. Mol. Ther., 2012, 20(5): 948-953.
31	KIMCHI-SARFATY C, OH J M, KIM I W, et al.. A "silent" polymorphism in the MDR1 gene changes substrate specificity[J]. Science, 2007, 315(5811): 525-528.
32	MAUGER D M, CABRAL B J, PRESNYAK V, et al.. mRNA structure regulates protein expression through changes in functional half-life[J]. Proc. Natl. Acad. Sci. USA, 2019, 116(48): 24075-24083.
33	WAYMENT-STEELE H K, KIM D S, CHOE C A, et al.. Theoretical basis for stabilizing messenger RNA through secondary structure design[J]. Nucleic Acids Res., 2021, 49(18): 10604-10617.
34	WENG Y, LI C, YANG T, et al.. The challenge and prospect of mRNA therapeutics landscape[J/OL]. Biotechnol. Adv., 2020, 40: 107534[2023-10-20]. .
35	LIN H H, HUANG L F, SU H C, et al.. Effects of the multiple polyadenylation signal AAUAAA on mRNA 3'-end formation and gene expression[J]. Planta, 2009, 230(4): 699-712.
36	SHULMAN E D, ELKON R. Systematic identification of functional SNPs interrupting 3'UTR polyadenylation signals[J/OL]. PLoS Genet., 2020, 16(8): e1008977[2023-10-20]. .
37	ORLANDINI VON NIESSEN A G, POLEGANOV M A, RECHNER C, et al.. Improving mRNA-based therapeutic gene delivery by expression-augmenting 3' UTRs identified by cellular library screening[J]. Mol. Ther., 2019, 27(4): 824-836.
38	HOLTKAMP S, KREITER S, SELMI A, et al.. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells[J]. Blood, 2006, 108(13): 4009-4017.
39	CHEN C Y, SHYU A B. AU-rich elements: characterization and importance in mRNA degradation[J]. Trends Biochem. Sci., 1995, 20(11): 465-470.
40	NICHOLSON A L, PASQUINELLI A E. Tales of detailed poly(A) tails[J]. Trends Cell Biol., 2019, 29(3): 191-200.
41	JALKANEN A L, COLEMAN S J, WILUSZ J. Determinants and implications of mRNA poly(A) tail size: does this protein make my tail look big?[J]. Semin. Cell Dev. Biol., 2014, 34: 24-32.
42	PELLETIER J, SONENBERG N. The organizing principles of eukaryotic ribosome recruitment[J]. Annu. Rev. Biochem., 2019, 88: 307-335.
43	SCHLAKE T, THESS A, FOTIN-MLECZEK M, et al.. Developing mRNA-vaccine technologies[J]. RNA Biol., 2012, 9(11): 1319-1330.
44	MOCKEY M, GONÇALVES C, DUPUY F P, et al.. mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly(A) chains in cis and in trans for a high protein expression level[J]. Biochem. Biophys. Res. Commun., 2006, 340(4): 1062-1068.
45	GRIER A E, BURLEIGH S, SAHNI J, et al.. pEVL: a linear plasmid for generating mRNA IVT templates with extended encoded poly(A) sequences[J/OL]. Mol. Ther. Nucleic Acids, 2016, 5: e306[2023-10-20]. .
46	POTAPOV V, FU X, DAI N, et al.. Base modifications affecting RNA polymerase and reverse transcriptase fidelity[J]. Nucleic Acids Res., 2018, 46(11): 5753-5763.
47	JIANG T, YU N, KIM J, et al.. Oligonucleotide sequence mapping of large therapeutic mRNAs via parallel ribonuclease digestions and LC-MS/MS[J]. Anal. Chem., 2019, 91(13): 8500-8506.
48	BEVERLY M, HAGEN C, SLACK O. Poly A tail length analysis of in vitro transcribed mRNA by LC-MS[J]. Anal. Bioanal. Chem., 2018, 410(6): 1667-1677.
49	CHALLENER C. Analysis of mRNA therapeutics and vaccines[J]. BioPharm. International., 2022, 35 (2):10-15.
50	RICH A. The double helix: a tale of two puckers[J]. Nat. Struct. Mol. Biol., 2003, 10: 247-249.
51	HENDRIX D K, BRENNER S E, HOLBROOK S R. RNA structural motifs: building blocks of a modular biomolecule[J]. Q. Rev. Biophys., 2005, 38(3): 221-243.
52	BUTCHER S E, PYLE A M. The molecular interactions that stabilize RNA tertiary structure: RNA motifs, patterns, and networks[J]. Acc. Chem. Res., 2011, 44(12): 1302-1311.
53	D'ASCENZO L, LEONARSKI F, VICENS Q, et al.. Revisiting GNRA and UNCG folds: U-turns versus Z-turns in RNA hairpin loops[J]. RNA, 2017, 23(3): 259-269.
54	SCHROEDER K T, MCPHEE S A, OUELLET J, et al.. A structural database for k-turn motifs in RNA[J]. RNA, 2010, 16(8): 1463-1468.
55	EGLI M, MINASOV G, SU L, et al.. Metal ions and flexibility in a viral RNA pseudoknot at atomic resolution[J]. Proc. Natl. Acad. Sci. USA, 2002, 99(7): 4302-4307.
56	BATEY R T, RAMBO R P, DOUDNA J A. Tertiary motifs in RNA structure and folding[J]. Angew. Chem. Int. Ed. Engl., 1999, 38(16): 2326-2343.
57	YU C, GABRIELE V. RNA Structure[M]. Willey Online Library,2020.
58	TAMURA M, HOLBROOK S R. Sequence and structural conservation in RNA ribose zippers[J]. J. Mol. Biol., 2002, 320(3): 455-474.
59	SHI X, KHADE P K, SANBONMATSU K Y, et al.. Functional role of the sarcin-ricin loop of the 23S rRNA in the elongation cycle of protein synthesis[J]. J. Mol. Biol., 2012, 419(3-4): 125-138.
60	HUANG L, LIAO X, LI M, et al.. Structure and folding of four putative kink turns identified in structured RNA species in a test of structural prediction rules[J]. Nucleic Acids Res., 2021, 49(10): 5916-5924.
61	LI B, CAO Y, WESTHOF E, et al.. Advances in RNA 3D structure modeling using experimental data[J/OL]. Genetics, 2020, 11: 574485[2023-10-20]. .
62	SEETIN M G, MATHEWS D H. RNA structure prediction: an overview of methods[J]. Meth. Mol. Biol., 2012, 905: 99-122.
63	MAUGERI M, NAWAZ M, PAPADIMITRIOU A, et al.. Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells[J/OL]. Nat. Commun., 2019, 10: 4333[2023-10-20]. .
64	WANG Y S, KUMARI M, CHEN G H, et al.. mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications[J/OL]. J. Biomed. Sci., 2023, 30(1): 84[2023-10-20]. .
65	WHITAKER J A, SAHLY H M E, HEALY C M. mRNA vaccines against respiratory viruses[J]. Curr. Opin. Infect. Dis., 2023, 36(5): 385-393.
66	HOU F, ZHANG Y, LIU X, et al.. mRNA vaccines encoding fusion proteins of monkeypox virus antigens protect mice from vaccinia virus challenge[J/OL]. Nat. Commun., 2023, 14: 5925[2023-10-20]. .
67	NAVEED M, WASEEM M, AZIZ T, et al.. Identification of bacterial strains and development of anmRNA-based vaccine to combat antibiotic resistance in Staphylococcus aureus via in vitro and in silico approaches[J/OL]. Biomedicines, 2023, 11(4): 1039[2023-10-20]. .
68	WANG X, LIU C, RCHEULISHVILI N, et al.. Strong immune responses and protection of PcrV and OprF-I mRNA vaccine candidates against Pseudomonas aeruginosa [J/OL]. NPJ Vaccines, 2023, 8: 76[2023-10-20]. .
69	HE Q, GAO H, TAN D, et al.. mRNA cancer vaccines: advances, trends and challenges[J]. Acta Pharm. Sin. B, 2022, 12(7): 2969-2989.
70	YOU H, JONES M K, GORDON C A, et al.. The mRNA vaccine technology era and the future control of parasitic infections[J/OL]. Clin. Microbiol. Rev., 2023, 36(1): e0024121[2023-10-20]. .
71	BORKENS Y. Malaria & mRNA vaccines: a possible salvation from one of the most relevant infectious diseases of the global south[J]. Acta Parasitol., 2023, 68(4): 916-928.
72	LE T, SUN C, CHANG J, et al.. mRNA vaccine development for emerging animal and zoonotic diseases[J/OL]. Viruses, 2022, 14(2): 401[2023-10-20]. .
73	HERRERA-ONG L R. Strategic construction of mRNA vaccine derived from conserved and experimentally validated epitopes of avian influenza type A virus: a reverse vaccinology approach[J]. Clin. Exp. Vaccine Res., 2023, 12(2): 156-171.
74	ROHNER E, YANG R, FOO K S, et al.. Unlocking the promise of mRNA therapeutics[J]. Nat. Biotechnol., 2022, 40: 1586-1600.
75	BARBIER A J, JIANG A Y, ZHANG P, et al.. The clinical progress of mRNA vaccines and immunotherapies[J]. Nat. Biotechnol., 2022, 40: 840-854.
76	LIU C, SHI Q, HUANG X, et al.. mRNA-based cancer therapeutics[J]. Nat. Rev. Cancer, 2023, 23: 526-543.
77	Pipeline of arcturus-owned mRNA therapeutic candidates[EB/OL].(2023-10-25)[2023-11-28]. .
78	AZD 8601 EPICCURE Phase II trial demonstrated safety and tolerability in patients with heart failure[EB/OL]. (2021-11-15)[2023-11-28]..
79	Safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy trial of BNT 141 in patients with unresectable or metastatic CLDN 18.2gastric-positive, pancreatic, ovarian and biliary tract tumors[EB/OL]. (2023-10-02)[2023-11-28]. .
80	SCHAEFER M, KAPOOR U, JANTSCH M F. Understanding RNA modifications: the promises and technological bottlenecks of the 'epitranscriptome'[J/OL]. Open Biol., 2017, 7(5): 170077[2023-10-20]. .
81	KIM D Y, ATASHEVA S, MCAULEY A J, et al.. Enhancement of protein expression by alphavirus replicons by designing self-replicating subgenomic RNAs[J]. Proc. Natl. Acad. Sci. USA, 2014, 111(29): 10708-10713.
82	MCKAY P F, HU K, BLAKNEY A K, et al.. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice[J/OL]. Nat. Commun., 2020, 11: 3523[2023-10-20]. .
83	WESSELHOEFT R A, KOWALSKI P S, ANDERSON D G. Engineering circular RNA for potent and stable translation in eukaryotic cells[J/OL]. Nat. Commun., 2018, 9: 2629[2023-10-20]. .
84	SASSO J M, AMBROSE B J B, TENCHOV R, et al.. The progress and promise of RNA medicine-an arsenal of targeted treatments[J]. J. Med. Chem., 2022, 65(10): 6975-7015.
85	PAUNOVSKA K, LOUGHREY D, DAHLMAN J E. Drug delivery systems for RNA therapeutics[J]. Nat. Rev. Genet., 2022, 23: 265-280.
86	ZHANG Y, SUN C, WANG C, et al.. Lipids and lipid derivatives for RNA delivery[J]. Chem. Rev., 2021, 121(20): 12181-12277.
87	CUI S, WANG Y, GONG Y, et al.. Correlation of the cytotoxic effects of cationic lipids with their headgroups[J]. Toxicol. Res., 2018, 7(3): 473-479.
88	XIA Y, TIAN J, CHEN X. Effect of surface properties on liposomal siRNA delivery[J]. Biomaterials, 2016, 79: 56-68.
89	CULLIS P R, HOPE M J. Lipid nanoparticle systems for enabling gene therapies[J]. Mol. Ther., 2017, 25(7): 1467-1475.
90	GREF R, MINAMITAKE Y, PERACCHIA M T, et al.. Biodegradable long-circulating polymeric nanospheres[J]. Science, 1994, 263(5153): 1600-1603.
91	SU S A, XIE Y, FU Z, et al.. Emerging role of exosome-mediated intercellular communication in vascular remodeling[J]. Oncotarget, 2017, 8(15): 25700-25712.
92	MA Y, LI X, ZHAO R, et al.. Creating de novo peptide-based bioactivities: from assembly to origami[J]. RSC Adv., 2022, 12(40): 25955-25961.
93	LLOREN K K S, JAWALAGATTI V, HEWAWADUGE C, et al.. Salmonella-mediated oral delivery of multiple-target vaccine constructs with conserved and variable regions of SARS-CoV-2 protect against the Delta and Omicron variants in hamster[J/OL]. Microbes Infect., 2023, 25(5): 105101[2023-10-20]. .
94	CUI H, ZHU X, LI S, et al.. Liver-targeted delivery of oligonucleotides with N-acetylgalactosamine conjugation[J]. ACS Omega, 2021, 6(25): 16259-16265.
95	DEBACKER A J, VOUTILA J, CATLEY M, et al.. Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug[J]. Mol. Ther., 2020, 28(8): 1759-1771.
96	CHENG Q, WEI T, FARBIAK L, et al.. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing[J]. Nat. Nanotechnol., 2020, 15: 313-320.
97	CHEN J, YE Z, HUANG C,et al.. Lipid nanoparticle-mediated lymph nodetargeting delivery of mRNA cancer vaccine elicits robust CD8⁺ T cell response[J/OL].Proc. Natl. Acad. Sci. USA,2022,119(34):e2207841119[2023-10-20]. .
98	MELAMED J R, YERNENI S S, ARRAL M L, et al.. Ionizable lipid nanoparticles deliver mRNA to pancreatic β cells via macrophage-mediated gene transfer[J/OL]. Sci. Adv., 2023, 9(4): eade1444[2023-10-20]. .
99	KIM J, JOZIC A, LIN Y, et al.. Engineering lipid nanoparticles for enhanced intracellular delivery of mRNA through inhalation[J]. ACS Nano, 2022, 16(9): 14792-14806.

[1]	门佩璇, 肖宇锋, 张玢. 基于计量学方法分析数字PCR技术的临床应用现状与技术热点[J]. 生物技术进展, 2022, 12(4): 606-613.
[2]	寻治铭,赵清辉,琚芳迪,何晋,姚婷婷,赵鹏翔,马雪梅,谢飞. 氢分子在临床应用中的研究进展[J]. 生物技术进展, 2019, 9(3): 217-222.
[3]	何洁, 郭采平. 人转铁蛋白的分离纯化及临床应用进展[J]. 生物技术进展, 2019, 9(1): 28-34.
[4]	陆腾飞,邬杨楠,裴文华,马月辉,关伟军. 内皮祖细胞的生物学特性及其应用[J]. 生物技术进展, 2017, 7(4): 266-271.

mRNA药物的结构和临床应用

Structure and Clinical Application of mRNA Drugs

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 99

相关文章 4

编辑推荐

Metrics

本文评价